(Bloomberg) -- Latigo Biotherapeutics Inc. filed for an initial public offering, joining a growing list of biotechnology firms considering going public as soon as this quarter.Most Read from BloombergFCC Near Rulings Against Disney Over ‘The View,’ TV LicensesChipmakers Bounce After Plunge to Bear-Market Edge: Markets WrapGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsChina’s Moonshot Unveils AI Model That Narrows Gap With US FirmsThailand Scraps Plan to End Visa-Free Entry fo
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
63last 24h
973last 7d
109● bullish (7d)
123● bearish (7d)
212publishers
Bloomberg64d agoneutral
Blue Owl-Backed Latigo Files for IPO, Adding to Biotech Pipeline